Immune cell therapy against disseminated melanoma by utilizing induced pluripotent stem cell-derived myeloid cell lines producing interferon-beta or interleukin-15/interleukin-15 receptor alpha

Mizuhashi, Satoru; Kubo, Yosuke; Fukushima, Satoshi; Kanemaru, Hisashi; Miyasita, Azusa; Ishibashi, Takayuki; Kuriyama, Haruka; Kimura, Toshihiro; Masuguchi, Shinichi; Zhang, Rong; Iwama, Tatsuaki; Nakatsura, Tetsuya; Uemura, Yukari; Senju, Satoru; Ihn, Hironobu

doi:10.1016/j.jdermsci.2021.03.005

Cited by 3 publications

(5 citation statements)

References 10 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…42 Mouse iPSC-pMCs genetically modified to produce IL-15 and IL-15/Rα (iPSC-pMC-IL-15/Rα) enhanced the cytotoxic activity of NK cells in mice and significantly suppressed tumour growth. 14 Combination therapy with iPSC-pMC-IFNβ, which had the best antitumor effect in previous studies, showed marked efficacy. iPSC-pMC-IFNβ and iPSC-pMC-IL-15/Rα combination therapy may be effective in overcoming tumour immune escape, including loss of MHC class I molecules.…”

Section: Ipsc-derived Prolifer Ating M C Smentioning

confidence: 96%

“…10,11 Similar to conventional DCs, iPS-DCs can activate T cells by antigen presentation, and iPS-MPs migrate towards cancer and attack it. [12][13][14][15] As iPS-T, iPS-NKT, iPS-NK, iPS-DCs and iPS-MPs use iPSC as the source, genetic modification is easy, and various immune functions such as anti-tumour cytokine production can be added. In the following sections, we review how we designed our study with the idea of iPS-DCs and iPS-MPs and what kinds of genetically modified iPS-DCs or MPs have been created.…”

Section: T Ype S Of Ipsc-ba S Ed C An Cer Immunother Apymentioning

confidence: 99%

“…On the other hand, Senju et al 10,11 from Kumamoto University have established a method to generate DCs and MPs from iPSCs (iPS‐DCs and iPS‐MPs, respectively) 10,11 . Similar to conventional DCs, iPS‐DCs can activate T cells by antigen presentation, and iPS‐MPs migrate towards cancer and attack it 12–15 . As iPS‐T, iPS‐NKT, iPS‐NK, iPS‐DCs and iPS‐MPs use iPSC as the source, genetic modification is easy, and various immune functions such as anti‐tumour cytokine production can be added.…”

Section: Types Of Ipsc‐based Cancer Immunotherapymentioning

confidence: 99%

“…Mizuhashi et al 14 investigated the possibility of treating mouse melanoma with major histocompatibility complex (MHC) class I loss using gene‐modified iPSC‐pMCs. Recently, the problem of some patients not responding to immune checkpoint inhibitors has become an issue; one of the causes of this is the loss of MHC class I in tumours 41 .…”

Section: Ipsc‐derived Proliferating Mcsmentioning

confidence: 99%

“…IL‐15 plays an important role in the activation of NK cell‐mediated cytotoxicity, and IL‐15 secretion is mediated by IL‐15 receptor alpha (IL‐15Rα) 42 . Mouse iPSC‐pMCs genetically modified to produce IL‐15 and IL‐15/Rα (iPSC‐pMC‐IL‐15/Rα) enhanced the cytotoxic activity of NK cells in mice and significantly suppressed tumour growth 14 . Combination therapy with iPSC‐pMC‐IFN‐β, which had the best antitumor effect in previous studies, showed marked efficacy.…”

Section: Ipsc‐derived Proliferating Mcsmentioning

confidence: 99%

See 4 more Smart Citations

Future prospects for cancer immunotherapy using induced pluripotent stem cell‐derived dendritic cells or macrophages

Fukushima

Miyashita

Kuriyama

et al. 2022

Experimental Dermatology

Self Cite

View full text Add to dashboard Cite

Immune checkpoint inhibitors, such as anti-programmed cell death (PD)-1 and anti-cytotoxic T lymphocyte-associated (CTLA)-4 antibodies, have fundamentally changed cancer treatments. Cancer immunotherapy is now the first-line treatment for many unresectable cancers. The development of drug therapies for cancer in the last decade has been largely centred on anti-PD-1 antibodies. In melanoma, immune checkpoint inhibitors have certainly shed some light on the dismal situation in which only dacarbazine, a cytotoxic anticancer drug, is available. However, it is by no means true that all patients have been cured. It is becoming clear that the efficacy of immune checkpoint inhibitors in patients with acral or mucosal melanoma is inferior to that of cutaneous melanoma. [1][2][3][4] The drug discovery and development process may come to a standstill at some point, even if its focus on immune checkpoint inhibitors continues for the next 10 years, and it is necessary to develop some innovative methods for cancer immunotherapy. From these perspectives, we believe that the era of cell therapy will arrive in the next 10 years. Dermatologists already use epidermal culture sheets in clinical practice as an example of using cells as drugs. 5 In the field of cancer immunotherapy, chimeric antigen receptor (CAR)-T cells have been approvedfor treating B-cell leukaemia and other types of cancer. 6 However, Kymriah®︎, a CAR-T-targeting CD19, has shown a high response rate, but its price tag of approximately USD 475000 has become a hot topic. Our group has been conducting research on the generation

show abstract

Section: Ipsc-derived Prolifer Ating M C Smentioning

confidence: 96%